# Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

> **NCT04337970** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Kidney Cancer
- Renal Cell Carcinoma
- Unresectable Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Talazoparib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04337970
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-06
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-05-23
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337970, "Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04337970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*